Acrivon Therapeutics COO Eric Devroe buys 10,000 shares at $1.72/share on Jan 13.

Acrivon Therapeutics, Inc. (ACRV) has recently announced that Devroe Eric, its Chief Operating Officer, has made a notable investment in the company. Specifically, on January 13, 2026, Eric purchased a substantial 10,000 shares at a price of $1.72 per share. This investment serves as a testament to the company's potential and demonstrates Eric's confidence in its future prospects.